



**FY 10**


# **IRB Submission Report**

Compiled by Cindy McConaughy-Smith  
Research Integrity Office

Date: 8/7/09


# IRQ Submissions YTD

<b>Federal</b>	<b>25</b>
<b>Foundation</b>	<b>15</b>
<b>Industry</b>	<b>16</b>
<b>Internal</b>	<b>66</b>
<b>Total</b>	<b>122</b>



# Top 5 Department IRQ Submissions YTD FY10


<b>Hematology</b>	<b>9</b>
<b>Surgery</b>	<b>9</b>
<b>Pediatric</b>	<b>13</b>
<b>Ophthalmology</b>	<b>9</b>
<b>Neurology</b>	<b>12</b>
<b>Other*</b>	<b>70</b>
<b>Total</b>	<b>122</b>



- \*Remaining 32 departments
- 31% of the top five submitting department protocols required oncology review
- 22% of all IRQ submissions required oncology review

# IRQ Review Categories YTD FY10

Anticipated Human Research	1
Exempt	14
Expedited	65
Full Board	42
Non-Human Subjects Research	6
Waived	6



**Key:**

**Anticipated Human Subjects :** (1) Definite plans for involvement of human subjects are not available at the time of funding; and /or (2) Awards that support multiple projects, each of which will obtain its own IRB approval.


**Exempt:** Protocols meeting the federal regulations for this level of IRB Review.

**Expedited :** Protocols involving no more than minimal risk.

**Full Board:** Protocols that require review by the convened OHSU IRB .

**Non Human Subjects:** Protocols not meeting the federal definition of "human subjects research."

**Waived:** Protocols where OHSU's IRB agrees to waive oversight to another IRB



# CRQ Submissions YTD


**Federal 100**

**Foundation 36**

**Industry 53**


**Internal 127**

**Total 316**



# Modification Submissions YTD

<b>Federal</b>	<b>242</b>
<b>Foundation</b>	<b>53</b>
<b>Industry</b>	<b>190</b>
<b>Internal</b>	<b>112</b>
<b>Total</b>	<b>597</b>



# Unanticipated Problem Submissions YTD

<b>Federal</b>	<b>2</b>
<b>Foundation</b>	<b>1</b>
<b>Industry</b>	<b>30</b>
<b>Internal</b>	<b>1</b>
<b>Total</b>	<b>34</b>

